Annogen_Logo_white.png
an_banners (6).png

SuRE™ Technology Screening services


Identification of regulatory DNA elements and non-coding genetic variants that underlie traits and diseases in humans, plants and animals.

 

Cell Therapy

an_icons.png

SuRE™ screening to identify promoters for better control over the expression of your transgene.

Non-Coding Genomics

an_icons (1).png

Assay the functional impact of non-coding mutations for entire genomes or specific mutation panels.

Drug Discovery

an_icons (2).png

SuRE™ reporter libraries for monitoring of multiple pathways during compound screens.

Recombinant Protein Production

an_icons (3).png

Dedicated SuRE™ screens in specific production platforms to identify optimal promoters for increased yields.

 
an_banners (10).png

Our novel technology in 2 steps

The SuRE method is in essence a strategy to analyze millions of DNA elements for their activity as promoters or enhancers in a single experiment. By analyzing ~300 million DNA elements of ~300bp length, an entire human genome can be analyzed exhaustively at an approximate 30 fold coverage.


The only required input is DNA and once a SuRE library is established it can be analyzed and compared to other DNA sources in the controlled environment of any transfectable cell type. Thus, without the requirement of invasive biopsies, any genome of interest can be analyzed in relevant cell types and under relevant (e.g. stimulatory) conditions.

Screenshot 2020-02-17 at 14.00.51.png

1

Library Construction

We first construct a plasmid library containing millions of DNA elements. A human genome is randomly sheared, size-selected and cloned into a plasmid library that contains no promoter of its own. These plasmids contain a unique 20bp sequence referred to as a barcode which allows us to uniquely identify and follow each cloned DNA element. This library is characterized (i.e. barcodes are associated to their respective DNA element) by paired-end sequencing.

9.png

barcoded plasmid

Fragmented human genome

0.2 - 2 kb

8.png
9.png

barcoded plasmid

10.png

Plasmid library containing > 300 million DNA elements

2

Library Expression Profiling

In step 2, the plasmid library is transfected into a cell type of interest. DNA elements containing promoters or enhancers will transcribe the barcode which can now be detected in the RNA by high-throughput sequencing. By comparing these barcode frequencies with the frequencies in the plasmid library, a quantitative map of promoter and enhancer activity can be constructed for the human genome. 

Transfection plasmid library into ~1*10  cells

8

Annogen_step2.1png.png

Quantify expressed barcodes

Quantify all barcodes

('input')

Ratio

Promoter and enhancer activity for entire genome

Allogen_355.png
Annogen)greenbluebarthin.png
 

Introducing our experts

We have a team of ten highly skilled and enthusiastic scientists and technicians dedicated to our clients projects. In addition, they work on new developments around our SuRE™ platform to ensure its continuous improvement for pharmaceutical and agricultural applications. The team is led by founder Joris van Arensbergen and biotech entrepreneur Victor Schut.

 

Recent news

sign.jpg

Vacancy

VACANCY – Part-Time Position Office Manager 

We are looking for an energetic and motivated office manager for our growing company. Tasks will be focused on professionalization of our organization including HR, administration, logistics etc. We are looking for someone that can identify tasks him/herself and that enjoys taking the initiative. The job will be for 12-20 hours per week, ideally 3 or 5 half days but this is flexible and can be discussed.

sign.jpg

NEWS

PRESS RELEASE – Amsterdam, 30 November 2021 Annogen BV, a precision medicine company for the non-coding genome, signs research agreement with top tier pharma company. 

Under the agreement Annogen will use its proprietary SuRE™ technology to generate genome-wide regulatory profiles to identify disease-relevant regulatory activity and disease-relevant non-coding sequence variants.

sign.jpg

NEWS

Annogen signs collaboration agreement with Tier 1 agricultural firm to research non-coding DNA influencing gene expression using SuRE™ screening technology

Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agricultural firm to identify non-coding DNA fragments in plants’ genomes that influence the expression of important crop traits. This will open new possibilities to intentionally upregulate or downregulate the expression of important genes in crops.

sign.jpg

NEWS

Annogen and KeyGene to collaborate in research on non-coding DNA influencing gene expression

Annogen and KeyGene the Wageningen based research company developing innovative technologies for crop improvement, are to collaborate in identifying non-coding DNA fragments in plants’ genomes that influence the expression of important crop traits. This will open new possibilities to intentionally upregulate or downregulate the expression of important genes in crops.

sign.jpg

NEWS

Annogen incorporated to commercialize SuRE technology for Functional Genome Annotation.

Sister company Gen-X BV has just signed an exclusive deal for use of SuRE for gene therapy with uniQure and consequently, Annogen was incorporated with exclusive rights to commercialize the technology outside the gene therapy field.

Annogen_Victor2.jpg

CBO APPOINTED

February 1, 2020 - Annogen appoints Victor Schut as Chief Business Officer

After supporting sister company Gen-X as CBO in 2019 and following the recent execution of its exclusive deal with Dutch gene therapy company uniQure he will now focus on setting up the spin-off business around the SuRE technology outside the gene therapy field.

Follow our activities on LinkedIn

  • LinkedIn - White Circle
an_banners (8).png